ombrabulin
Small moleculeexperimental
Ombrabulin was an experimental drug candidate discovered by Ajinomoto and further developed by Sanofi-Aventis. Ombrabulin is a combretastatin A-4 derivative that exerts its antitumor effect by disrupting the formation of blood vessels needed for tumor growth. — Wikipedia
Clinical trial activity
11 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Jun 1, 2006 (NCT01907685)
Timeline
Indications
Mechanism of action
- TubulinINHIBITOR
Tubulin inhibitor
- Tubulin beta-4B chain (TUBB4B) ↗
- Tubulin beta-1 chain (TUBB1) ↗
- Tubulin alpha-3C chain (TUBA3C) ↗
- Tubulin alpha-4A chain (TUBA4A) ↗
- Tubulin beta-3 chain (TUBB3) ↗
- Tubulin alpha-1A chain (TUBA1A) ↗
- Tubulin beta-4A chain (TUBB4A) ↗
- Tubulin beta-8 chain (TUBB8) ↗
- Tubulin beta chain (TUBB) ↗
- Tubulin alpha-1B chain (TUBA1B) ↗
- Tubulin alpha-1C chain (TUBA1C) ↗
- Tubulin alpha-3E chain (TUBA3E) ↗
- Tubulin beta-2A chain (TUBB2A) ↗
- Tubulin beta-2B chain (TUBB2B) ↗
- Tubulin beta-6 chain (TUBB6) ↗
Chemistry & pharmacology
Loading structure…
SMILES
COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)[C@@H](N)CO- Mol. weight
- 402.45 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaOmbrabulin ↗
- ChEMBLCHEMBL572284 ↗
Also known as
- ac 7700
- ac-7700
- ave8062
- ave8062
- ave8062
- n-(2-methxoy-5-(2-(3,4,5-trimethoxyphenyl)vinyl)pheyl)-serinamide hydrochloride
- ombrabulin
- ombrabulin
- ombrabulin
- ombrabulin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01332656 | Phase 2 | May 1, 2011 | Sanofi |
| NCT01263886 | Phase 2 | Feb 1, 2011 | Sanofi |
| NCT01293630 | Phase 1 | Jan 1, 2011 | Sanofi |
| NCT01193595 | Phase 1 | Sep 1, 2010 | Sanofi |
| NCT01095302 | Phase 1 | May 1, 2010 | Sanofi |
| NCT01021150 | Phase 1 | Mar 1, 2010 | Sanofi |
| NCT01063946 | Phase 1 | Jan 1, 2010 | Sanofi |
| NCT00968916 | Phase 1 | Sep 1, 2009 | Sanofi |
| NCT00719524 | Phase 1 | Jul 1, 2008 | Sanofi |
| NCT00699517 | Phase 3 | Jun 1, 2008 | Sanofi |
| NCT01907685 | Phase 1 | Jun 1, 2006 | Sanofi |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sanofi | For profit | 11 | 11 | 3 | 2006 |
1 organizations
Page 1 / 1